•  
  •  
 

Abstract

Background: Rhabdomyolysis is a potentially lethal range of symptoms results from muscle cell destruction. It is recognized by the escape of cell contents such as myoglobin, creatine kinase, and electrolyte into the bloodstream then undergo glomeruli filtering. Therefore, among the most dangerous complication of rhabdomyolysis is acute renal injury. The complex and interrelated processes underlying rhabdomyolysis that ends with acute kidney injury include obstruction and damage of tubules, inflammation, and intrarenal vasoconstriction (activation of the sympathetic, renin-angiotensin).Glycerol is frequently used to inflict this kind of harm when used as a single dose injection that given intramuscularly to an animal model.

Aim of study: This study aims to evaluate the reno protective effect of ticagrelor in rat model of rhabdomyolysis condition (caused by glycerol injection) that leads to acute kidney injury.

Methods: Sprague Dawley adult male rats (thirty-five) were classified into (A) group of control (B) group of vehicles (C) induction group(glycerol) (D) vehicle with induction group (E) ticagrelor with induction group. The markers used in this study which include renal function tests (blood urea nitrogen and serum creatine) were measured by chemical analysis while interleukin one beta and caspase3 were measured by enzyme-linked immunosorbent assay.

Results: when comparing the induction group(glycerol) to the group of control there is a significant increase in the serum creatine as well as blood urea nitrogen and renal tissue interleukin one beta in addition to renal tissue caspase3,on other hand all these markers reduced in the group of ticagrelor in contrast to induction group.

Conclusion: Ticagrelor reduced renal dysfunction in rhabdomyolysis caused by glycerol via reducing the potential for apoptosis and the body's response to inflammation in addition to its antiplatelets impact.

References

References

[1] Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev 2016; 37(2):85-98.

[2] Mehta RL, Cerd_a J, Burdmann EA, Tonelli M, García- García G, Jha V, et al. International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet (London, England) 2015;385(9987):2616-43. https://doi.org/ 10.1016/S0140-6736(15)60126-X.

[3] Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet (London, England) 2005;365(9457):417-30. https:// doi.org/10.1016/S0140-6736(05)17831-3.

[4] Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med 2008;36(4 Suppl):S216-23. https://doi.org/10.1097/CCM.0b013-318168-375.

[5] Goyal A, Daneshpajouhnejad P, Hashmi MF, Bashir K, John BK. Acute kidney injury (nursing)

Updated 2023 Nov 25]. In: StatPearls

Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. https://www.ncbi.nlm.nih.gov/books/ NBK568593/.

[6] Madkour AH, Helal MG, Said E, Salem HA. Dose-dependent renoprotective impact of Lactoferrin against glycerolinduced rhabdomyolysis and acute kidney injury. Life Sci 2022;302:120646. https://doi.org/10.1016/j.lfs.2022.120646.

[7] Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Disease-a-month 2020;66(8):101015. https:// doi.org/10.1016/j.disamonth.2020.101015.

[8] Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Intern Med 2007;18(2):90-100. https://doi.org/10.1016/j.ejim.2006. 09.020.

[9] Burgess S. Rhabdomyolysis: an evidence-based approach. J Intensive Care Soc 2022;23(4):513-7. https://doi.org/ 10.1177/17511437211050782.

[10] Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis – an overview for clinicians. Crit Care 2005;9(2):158-69. https://doi.org/10.1186/cc2978.

[11] Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJ, de Visser M. Rhabdomyolysis: review of the literature. Neuromuscul Disord 2014;24(8):651-9. https://doi.org/10.1016/ j.nmd.2014.05.005.

[12] Singh AP, Junemann A, Muthuraman A, Jaggi AS, Singh N, Grover K, et al. Animal models of acute renal failure. Pharmacol Rep : PR 2012;64(1):31-44. https://doi.org/10.1016/ s1734-1140(12)70728-4.

[13] Navarese EP, Buffon A, Kozinski M, Obonska K, Rychter M, Kunadian V, et al. A critical overview on ticagrelor in acute coronary syndromes. QJM 2013;106(2):105-15. https:// doi.org/10.1093/qjmed/hcs187.

[14] Evans RG, Ince C, Joles JA, Smith DW, May CN, O'Connor PM, et al. Haemodynamic influences on kidney oxygenation: clinical implications of integrative physiology. Clin Exp Pharmacol Physiol 2013;40(2):106-22. https:// doi.org/10.1111/1440-1681.12031.

[15] Varenhorst C, Alstr€om U, Scirica BM, Hogue CW, Åsenblad N, Storey RF, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012;60(17):1623-30. https://doi.org/10.1016/ j.jacc.2012.07.021.

[16] Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2014;25(7):517-25. https:// doi.org/10.3109/09537104.2013.842965.

[17] Navarro KL, Huss M, Smith JC, Sharp P, Marx JO, Pacharinsak C. Mouse anesthesia: the art and science. ILAR J 2021;62(1-2):238-73. https://doi.org/10.1093/ilar/ilab016.

[18] Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol 2018;14(10):607-25. https://doi.org/10.1038/s41581-018-0052-0.

[19] Stahl K, Rastelli E, Schoser B. A systematic review on the definition of rhabdomyolysis. J Neurol 2020;267(4):877-82. https://doi.org/10.1007/s00415-019-09185-4.

[20] Belliere J, Casemayou A, Ducasse L, Zakaroff-Girard A, Martins F, Iacovoni JS, et al. Specific macrophage subtypes influence the progression of rhabdomyolysis-induced kidney injury. J Am Soc Nephrol 2015;26(6):1363-77. https://doi.org/ 10.1681/ASN.2014040320.

[21] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120(4):c179-84. https://doi.org/10.1159/000339789.

[22] Komada Takanori, Usui Fumitake, Kawashima Akira, Kimura Hiroaki, Karasawa Tadayoshi, Inoue Yoshiyuki, et al. Role of NLRP3 inflammasomes for rhabdomyolysis-induced acute kidney injury. Sci Rep 2015;5:10901. https://doi.org/ 10.1038/srep10901.

[23] Hareedy MS, Abdelzaher LA, Badary DM, Mohammed Alnasser S, Abd-Eldayem AM. Valproate attenuates hypertonic glycerol-induced rhabdomyolysis and acute kidney injury. N_ephrol Th_erapeutique 2021;17(3):160-7. https:// doi.org/10.1016/j.nephro.2020.12.003.

[24] Wu J, Pan X, Fu H, Zheng Y, Dai Y, Yin Y, et al. Effect of curcumin on glycerol-induced acute kidney injury in rats. Sci Rep 2017;7(1):10114. https://doi.org/10.1038/s41598-017- 10693-4.

[25] Yu C, Gao CM, Xie N, Wang XQ, Ma YQ. Effect of ticagrelor on acute kidney injury in septic rats and its underlying mechanism. Exp Ther Med 2021;21(5):475. https://doi.org/ 10.3892/etm.2021.9906.

[26] Li X, Li Y, Shen K, Li H, Bai J. The protective effect of ticagrelor on renal function in a mouse model of sepsis-induced acute kidney injury. Platelets 2019;30(2):199-205. https:// doi.org/10.1080/09537104.2017.1392499.

[27] Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003;31(4):1250-6. https://doi.org/10.1097/01.CCM.000005045 4.01978.3B.

[28] Kral JB, Schrottmaier WC, Salzmann M, Assinger A. Platelet interaction with innate immune cells. Transfus Med Hemotherapy 2016;43(2):78-88. https://doi.org/10.1159/000444807.

[29] Kiley SC, Thornhill BA, Belyea BC, Neale K, Forbes MS, Luetteke NC, et al. Epidermal growth factor potentiates renal cell death in hydronephrotic neonatal mice, but cell survival in rats. Kidney Int 2005;68(2):504-14. https://doi.org/10.1111/ j.1523-1755.2005.00428.x.

[30] Kappelmayer J, Nagy Jr B. The interaction of selectins and PSGL-1 as a key component in thrombus formation and cancer progression. BioMed Res Int 2017;2017:6138145. https://doi.org/10.1155/2017/6138145.

[31] Feliu C, Peyret H, Brassart-Pasco S, Oszust F, Poitevin G, Nguyen P, et al. Ticagrelor prevents endothelial cell apoptosis through the adenosine signalling pathway in the early stages of hypoxia. Biomolecules 2020;10(5):740. https:// doi.org/10.3390/biom10050740.

[32] Findik O, Kunt AT, Yazir Y, Yardimo_glu M, Yilmaz SG, Aydin U, et al. Ticagrelor attenuates apoptosis of lung and myocardial cells induced by abdominal aorta ischemia/ reperfusion. In vivo (Athens, Greece) 2016;30(3):243-9.

[33] Panizo N, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, Moreno JA. Molecular mechanisms and novel therapeutic approaches to rhabdomyolysis-induced acute kidney injury. Kidney Blood Pres Res 2015;40(5):520-32. https://doi.org/ 10.1159/000368528.

[34] Wu SY, Tang SE, Ko FC, Wu GC, Huang KL, Chu SJ. Valproic acid attenuates acute lung injury induced by ischemiareperfusion in rats. Anesthesiology 2015;122(6):1327-37. https://doi.org/10.1097/ALN.0000000000000618.

[35] Mahmood YS, Kathem SH. Protective effect of citronellol in rhabdomyolysis-induced acute kidney injury in mice. J Med Life 2023;16(7):1057-61. https://doi.org/10.25122/jml-2023-0102.

[36] Huang B, Qian Y, Xie S, Ye X, Chen H, Chen Z, et al. Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y12 signaling pathway. Cell Mol Immunol 2021;18(5):1278-89. https:// doi.org/10.1038/s41423-020-0444-5.

[37] Jansen MPB, Florquin S, Roelofs JJTH. The role of platelets in acute kidney injury. Nat Rev Nephrol 2018;14(7):457-71. https://doi.org/10.1038/s41581-018-0015-5.

[38] Oishi S, Tsukiji N, Otake S, Oishi N, Sasaki T, Shirai T, et al. Heme activates platelets and exacerbates rhabdomyolysisinduced acute kidney injury via CLEC-2 and GPVI/FcRg. Blood Adv 2021;5:2017-26. https://doi.org/10.1182/blood advances.2020001698.

[39] Jia Z, Huang Y, Ji X, Sun J, Fu G. Ticagrelor and clopidogrel suppress NF-kB signaling pathway to alleviate LPS-induced dysfunction in vein endothelial cells. BMC Cardiovasc Disord 2019;19(1):318. https://doi.org/10.1186/s12872-019- 01287-1.

Download

Share

COinS